|
Sign In to gain access to subscriptions and/or personal tools.
|
New Perspectives on the Management of Type 2 DiabetesReport of symposia at the Royal College of Physicians, London, 16 April 2008 and Hilton Hotel, Coventry, 14 May 2008
Anthony Barnett
Graham Hitman
Eugene Hughes
19 The Esplanade Ryde Isle of Wight PO33 2EH, Eugene.Hughes{at}gp-j84005.nhs.uk
Kamlesh Khunti
References
- Sandbaek A., Griffin SJ, Rutten G., et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008; 51: 1127-34.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Eborall HC, Griffin SJ, Prevost AT, et al. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007; 335:486-9.[Abstract/Free Full Text]
- Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008; 299:1678-89.[Abstract/Free Full Text]
- Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48:438-45.[Abstract/Free Full Text]
- Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-96.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-25.[CrossRef][Medline]
[Order article via Infotrieve]
- Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.[Abstract/Free Full Text]
- Nauck M., Meininger G., Sheng D., Terranella L., Stein PP Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diab Obes Metab 2007; 9:194-205.[CrossRef]
- Sinclair AJ, Conroy SP, Bayer AJ Impact of diabetes on physical function in older people. Diabetes Care 2008; 31:233-5.[Abstract/Free Full Text]
- Shulman KI Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 2000; 15:548-61.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bellary S., O'Hare JP, Raymond NT, et al. Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial. Lancet 2008; 371:1769-76.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Khunti K., Gadsby R., Millett C., Majeed A., Davies M. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes. Diabet Med 2007; 24:1436-41.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Campbell S., Reeves D., Kontopantelis E., Middleton E., Sibbald B., Roland M. Quality of primary care in England with the introduction of pay for performance. N Engl J Med 2007; 357:181-90.[Free Full Text]
- Millett C., Gray J., Saxena S., Netuveli G., Khunti K., Majeed A. Ethnic disparities in diabetes management and pay-for-performance in the UK: the Wandsworth Prospective Diabetes Study. PLoS Med 2007; 4:e191.[CrossRef][Medline]
[Order article via Infotrieve]
The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 4,
198-205 (2008)
DOI: 10.1177/1474651408095332

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|